Skip to main content

Advertisement

SpringerLink
Log in

Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

To compare the heart rate increase side effect of different antimuscarinic drugs used in overactive bladder (OAB).

Methods

Overall 341 patients were consecutively randomized to take seven different antimuscarinic drugs between January 2014 and June 2016 at three institutions, and 250 patients who completed the follow-up visits were accepted into this study. Ninety-one patients who never came to visits were excluded. Drugs were classified into two groups as selective (darifenacin hydrobromide, solifenacin succinate and oxybutynin hydrochloride) and non-selective (fesoterodine fumarate, tolterodine tartrate, trospium chloride and propiverine hydrochloride) antimuscarinic drugs. The cardiac pulse rates and the blood pressures were recorded during the baseline, first visit (1 week) and second visit (1 month). Data were compared for drugs and two groups (selective versus non-selective) by using ANOVA test.

Results

Baseline characteristics were similar among the patients using different antimuscarinic drugs. Statistically significant increase in heart rate occurred in patients treated with non-selective antimuscarinic drugs compared to those treated with selective drugs (p < 0.001), and this increase was especially evident in patients treated with trospium chloride, tolterodine tartrate, fesoterodine fumarate and propiverine hydrochloride (p < 0.001, 0.003, 0.011 and 0.37, respectively). There was no statistical difference for the other side effects.

Conclusions

Our results showed that heart rate significantly increased in OAB patients treated with non-selective antimuscarinic drugs. Trospium chloride, tolterodine tartrate, fesoterodine fumarate and propiverine hydrochloride seem to have the most unfavorable properties with regard to increased heart rate side effect when compared to the other antimuscarinic drugs (darifenacin hydrobromide, solifenacin succinate and oxybutynin hydrochloride).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178

    Article  Google Scholar 

  2. Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766

    Article  CAS  PubMed  Google Scholar 

  3. Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336

    CAS  PubMed  Google Scholar 

  4. Safarinejad MR (2009) Prevalence of the overactive bladder among Iranian women based on the International Continence Society definition: a population-based study. Int Urol Nephrol 41(1):35–45

    Article  PubMed  Google Scholar 

  5. Hashim H, Beusterien K, Bridges JF, Amos K, Cardozo L (2015) Patient preferences for treating refractory overactive bladder in the UK. Int Urol Nephrol 47(10):1619–1627

    Article  CAS  PubMed  Google Scholar 

  6. Abrams P, Andersson KE, Buccafusco JJ et al (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565–578

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Andersson K-E, Campeau L, Olshansky B (2011) Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol 72:186–196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Harvey RD, Belevych AE (2003) Muscarinic regulation of cardiac ion channels. Br J Pharmacol 139:1074–1084

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hozawa A, Ohkubo T, Kikuya M et al (2004) Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama Study. Am J Hypertens 17:1005–1010

    PubMed  Google Scholar 

  10. Jouven X, Empana JP, Escolano S et al (2009) Relation of heart rate at rest and long-term (> 20 years) death rate in initially healthy middle-aged men. Am J Cardiol 103:279–283

    Article  PubMed  Google Scholar 

  11. Hsia J, Larson JC, Ockene JK et al (2009) Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ 338:b219

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein DA (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and metaanalysis. Eur Urol 54:543–562

    Article  CAS  PubMed  Google Scholar 

  13. Novara G, Galfano A, Secco S et al (2008) A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 54:740–763

    Article  CAS  PubMed  Google Scholar 

  14. Cetinel B, Onal B (2013) Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. Korean J Urol 54(12):806–815

    Article  PubMed  PubMed Central  Google Scholar 

  15. Tarcan T, Mangir N, Ozgur MO, Akbal C (2012) Validation study of Turkish version of OAB-V8 overactive bladder questionnaire. Uroloji Bulteni 21:113–116

    Google Scholar 

  16. Andersson KE, Sarawate C, Kahler KH et al (2010) Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 106:268–274

    Article  PubMed  Google Scholar 

  17. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S, Trospium Study Group (2004) Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171:2311–2315

    Article  CAS  PubMed  Google Scholar 

  18. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R (2006) Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 67:275–280

    Article  PubMed  Google Scholar 

  19. Breuel HP, Mürtz G, Bondy S, Horkulak J, Gianetti BM (1993) Safety and tolerance of trospium chloride in the high dose range. Arzneimittelforschung 43:461–464

    CAS  PubMed  Google Scholar 

  20. Olshansky B, Ebinger U, Brum J et al (2008) Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, doubleblind, cross-over study with tolterodine tartrate and darifenacin in healthy participants> or = 50 years old. J Cardiovasc Pharmacol Ther 13:241–251

    Article  CAS  PubMed  Google Scholar 

  21. Olshansky B, Spierings E, Brum J et al (2009) Validation of the differential cardiovascular effects of the antimuscarinic agents, darifenacin and tolterodine tartrate, in a randomized, placebo-controlled, 3-way crossover study. UroToday Int J. https://doi.org/10.3834/uij.1944-5784.2009.08.07

    Article  Google Scholar 

  22. Schiffers M, Sauermann P, Schurch B, Mehnert U (2010) The effect of tolterodine tartrate 4 and 8 mg on the heart rate variability in healthy subjects. World J Urol 28:651–656

    Article  CAS  PubMed  Google Scholar 

  23. Chapple C, Van KP, Tubaro A et al (2007) Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 52:1204–1212

    Article  CAS  PubMed  Google Scholar 

  24. Abrams P, Cardozo L, Chapple C, Serdarevic D, Hargreaves K, Khullar V (2006) 1032 study group. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 13:692–698

    Article  CAS  PubMed  Google Scholar 

  25. Michel MC, Wetterauer U, Vogel M, de la Rosette JJMCH (2008) Cardiovascular safety and overall tolerability of solifenacin in routine clinical use. Drug Saf 31(6):505–514

    Article  CAS  PubMed  Google Scholar 

  26. Chapple CR, Abrams P (2005) Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Eur Urol 48:02–9

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, 34098, Istanbul, Turkey

    Bulent Cetinel, Bulent Onal, Mehmet Hamza Gultekin & Fethi Ahmet Turegun

  2. Department of Urology, Bursa Yuksek Ihtisas Education and Research Hospital, University of Health Sciences, Bursa, Turkey

    Muhammed Guzelsoy

  3. Department of Urology, Bagcilar Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

    Murat Dincer

Authors
  1. Bulent Cetinel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bulent Onal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mehmet Hamza Gultekin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Muhammed Guzelsoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fethi Ahmet Turegun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Murat Dincer
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

BC contributed to protocol/project development, manuscript writing/editing. BO, MHG helped with protocol/project development, data collection or management, data analysis, manuscript writing/editing. MG, FAT, MD involved in data collection or management.

Corresponding author

Correspondence to Bulent Cetinel.

Ethics declarations

Conflict of interest

Authors of this study have no conflict of interest.

Ethical approval

This open-label, prospective, multi-center, randomized and controlled follow-up study has institutional approval from Cerrahpasa School of Medicine Ethical Commitee with IRB number of 671/2014.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cetinel, B., Onal, B., Gultekin, M.H. et al. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial. Int Urol Nephrol 51, 417–424 (2019). https://doi.org/10.1007/s11255-019-02090-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-019-02090-9

Keywords

Search

Navigation